Natera (NTRA) Stock Forecast & Price Target

Compare

1,087 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NTRA Analyst Ratings

Strong Buy

16 Buy

0 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Natera

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NTRA Stock 12 Month Forecast

Average Price Target

$207.71

▲(25.35% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Natera in the last 3 months. The average price target is $207.71 with a high forecast of $255.00 and a low forecast of $190.00. The average price target represents a 25.35% change from the last price of $165.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"102":"$102","179":"$179","256":"$256","140.5":"$140.5","217.5":"$217.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":255,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$255.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":207.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$207.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$190.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[102,140.5,179,217.5,256],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,134.58,143.84307692307692,153.10615384615386,162.36923076923077,171.6323076923077,180.89538461538461,190.15846153846155,199.42153846153846,208.68461538461537,217.9476923076923,227.21076923076924,236.47384615384615,245.73692307692306,{"y":255,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,134.58,140.20538461538462,145.83076923076925,151.45615384615385,157.08153846153846,162.7069230769231,168.3323076923077,173.9576923076923,179.58307692307693,185.20846153846156,190.83384615384617,196.45923076923077,202.0846153846154,{"y":207.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,134.58,138.84307692307692,143.10615384615386,147.36923076923077,151.6323076923077,155.89538461538461,160.15846153846155,164.42153846153846,168.6846153846154,172.9476923076923,177.21076923076924,181.47384615384615,185.73692307692306,{"y":190,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":103,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.26,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.19,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.16,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":169.82,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.65,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.58,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$255.00

Average Price Target$207.71

Lowest Price Target$190.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tycho Peterson

Jefferies

$200

Buy

20.69%

Upside

Reiterated

08/25/25

Analysts Offer Insights on Healthcare Companies: Natera (NASDAQ: NTRA) and Theravance Biopharma (NASDAQ: TBPH)

Dan Leonard

UBS

$218

Buy

31.56%

Upside

Reiterated

08/19/25

Natera (NTRA) Receives a Buy from UBSUBS analyst Dan Leonard reiterated a Buy rating and $218.00 price target on Natera (NASDAQ: NTRA).

Cira Diagnissa

TR | OpenAI - 4o

$171→$177

Hold

6.81%

Upside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

Puneet Souda

Leerink Partners

―

Buy

―

Reiterated

08/18/25

Puneet Souda's Buy Rating on Natera Driven by Promising Signatera Trial Results and Market Growth Potential

Kyle Mikson CFA

Canaccord Genuity

$200

Buy

20.69%

Upside

Reiterated

08/12/25

Daniel Brennan

TD Cowen

$200→$215

Buy

29.74%

Upside

Reiterated

08/08/25

TD Cowen Keeps Their Buy Rating on Natera (NTRA)

Catherine Ramsey Schulte

Robert W. Baird

$194→$200

Buy

20.69%

Upside

Reiterated

08/08/25

Natera price target raised to $200 from $194 at BairdNatera price target raised to $200 from $194 at Baird

David Westenberg

Piper Sandler

$210

Buy

26.73%

Upside

Reiterated

08/08/25

Piper Sandler Sticks to Its Buy Rating for Natera (NTRA)

Rachel Vatnsdal

J.P. Morgan

$200→$210

Buy

26.73%

Upside

Reiterated

08/08/25

Natera (NTRA) Receives a Buy from J.P. MorganJPMorgan analyst Tycho W. Peterson raised the price target on Natera (NASDAQ: NTRA) to $210.00 (from $200.00) while maintaining a Overweight rating.

Eve Burstein

Bernstein

$200→$205

Buy

23.71%

Upside

Reiterated

08/08/25

Bernstein Sticks to Its Buy Rating for Natera (NTRA)Bernstein SocGen Group analyst Eve Burstein raised the price target on Natera (NASDAQ: NTRA) to $205.00 (from $200.00) while maintaining a Outperform rating.

Daniel Markowitz CFA

Evercore ISI

$170→$190

Buy

14.66%

Upside

Reiterated

08/08/25

Patrick Wood

Morgan Stanley

$195

Buy

17.68%

Upside

Reiterated

08/08/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (NASDAQ: CTKB), Natera (NASDAQ: NTRA) and Warby Parker (NYSE: WRBY)

Mark Massaro

BTIG

$195→$200

Buy

20.69%

Upside

Reiterated

08/08/25

Natera (NTRA) Gets a Buy from BTIG

Luke Sergott

Barclays

$190→$210

Buy

26.73%

Upside

Reiterated

08/08/25

Natera (NTRA) Gets a Buy from Barclays

William Bonello

Craig-Hallum

―

Buy

―

Reiterated

08/07/25

Craig-Hallum Sticks to Their Buy Rating for Natera (NTRA)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tycho Peterson

Jefferies

$200

Buy

20.69%

Upside

Reiterated

08/25/25

Analysts Offer Insights on Healthcare Companies: Natera (NASDAQ: NTRA) and Theravance Biopharma (NASDAQ: TBPH)

Dan Leonard

UBS

$218

Buy

31.56%

Upside

Reiterated

08/19/25

Natera (NTRA) Receives a Buy from UBSUBS analyst Dan Leonard reiterated a Buy rating and $218.00 price target on Natera (NASDAQ: NTRA).

Cira Diagnissa

TR | OpenAI - 4o

$171→$177

Hold

6.81%

Upside

Reiterated

08/19/25

AI Generated ArticleAI Generated Article

Puneet Souda

Leerink Partners

―

Buy

―

Reiterated

08/18/25

Puneet Souda's Buy Rating on Natera Driven by Promising Signatera Trial Results and Market Growth Potential

Kyle Mikson CFA

Canaccord Genuity

$200

Buy

20.69%

Upside

Reiterated

08/12/25

Daniel Brennan

TD Cowen

$200→$215

Buy

29.74%

Upside

Reiterated

08/08/25

TD Cowen Keeps Their Buy Rating on Natera (NTRA)

Catherine Ramsey Schulte

Robert W. Baird

$194→$200

Buy

20.69%

Upside

Reiterated

08/08/25

Natera price target raised to $200 from $194 at BairdNatera price target raised to $200 from $194 at Baird

David Westenberg

Piper Sandler

$210

Buy

26.73%

Upside

Reiterated

08/08/25

Piper Sandler Sticks to Its Buy Rating for Natera (NTRA)

Rachel Vatnsdal

J.P. Morgan

$200→$210

Buy

26.73%

Upside

Reiterated

08/08/25

Natera (NTRA) Receives a Buy from J.P. MorganJPMorgan analyst Tycho W. Peterson raised the price target on Natera (NASDAQ: NTRA) to $210.00 (from $200.00) while maintaining a Overweight rating.

Eve Burstein

Bernstein

$200→$205

Buy

23.71%

Upside

Reiterated

08/08/25

Daniel Markowitz CFA

Evercore ISI

$170→$190

Buy

14.66%

Upside

Reiterated

08/08/25

Patrick Wood

Morgan Stanley

$195

Buy

17.68%

Upside

Reiterated

08/08/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (NASDAQ: CTKB), Natera (NASDAQ: NTRA) and Warby Parker (NYSE: WRBY)

Mark Massaro

BTIG

$195→$200

Buy

20.69%

Upside

Reiterated

08/08/25

Natera (NTRA) Gets a Buy from BTIG

Luke Sergott

Barclays

$190→$210

Buy

26.73%

Upside

Reiterated

08/08/25

Natera (NTRA) Gets a Buy from Barclays

William Bonello

Craig-Hallum

―

Buy

―

Reiterated

08/07/25

Craig-Hallum Sticks to Their Buy Rating for Natera (NTRA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Natera

1 Month

xxx

Success Rate

12/15 ratings generated profit

Average Return

+9.47%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +9.47% per trade.

3 Months

xxx

Success Rate

12/15 ratings generated profit

Average Return

+17.82%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +17.82% per trade.

1 Year

Matthew SykesGoldman Sachs

Success Rate

14/15 ratings generated profit

Average Return

+74.23%

reiterated a buy rating 7 months ago

Copying Matthew Sykes's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +74.23% per trade.

2 Years

xxx

Success Rate

25/26 ratings generated profit

Average Return

+119.38%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 96.15% of your transactions generating a profit, with an average return of +119.38% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NTRA Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NTRA has received 25 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. NTRA average Analyst price target in the past 3 months is 207.71.

Each month's total comprises the sum of three months' worth of ratings.

NTRA Financial Forecast

NTRA Earnings Forecast

Next quarter’s earnings estimate for NTRA is -$0.38 with a range of -$0.63 to -$0.17. The previous quarter’s EPS was -$0.74. NTRA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.80% of the time in the same period. In the last calendar year NTRA has Outperformed its overall industry.

NTRA Sales Forecast

Next quarter’s sales forecast for NTRA is $513.34M with a range of $500.40M to $525.48M. The previous quarter’s sales results were $546.60M. NTRA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 43.50% of the time in the same period. In the last calendar year NTRA has Outperformed its overall industry.

NTRA Stock Forecast FAQ

What is NTRA’s average 12-month price target, according to analysts?

Based on analyst ratings, Natera’s 12-month average price target is 207.71.

What is NTRA’s upside potential, based on the analysts’ average price target?

Natera has 25.35% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NTRA a Buy, Sell or Hold?

Natera has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.

What is Natera’s price target?

The average price target for Natera is 207.71. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $255.00 ,the lowest forecast is $190.00. The average price target represents 25.35% Increase from the current price of $165.71.

What do analysts say about Natera?

Natera’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of NTRA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Natera (NTRA) Stock Forecast & Price Target

NTRA Analyst Ratings

NTRA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Natera

NTRA Analyst Recommendation Trends

NTRA Financial Forecast

NTRA Earnings Forecast

NTRA Sales Forecast

NTRA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts